Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 361-370

  Zembutsu, Hitoshi ^a   Suzuki, Yasuyo ^b   Sasaki, Aya ^b   Tsunoda, Tatsuhiko ^c   Okazaki, Minoru ^d   Yoshimoto, Masataka ^e   Hasegawa, Tadashi ^b   Hirata, Koichi ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c RIKEN   (Japan)

^d Sapporo Nyusen Geka Clinic   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Breast cancer; Docetaxel; Gene expression profile; Microarray; Neoadjuvant chemotherapy; Prediction

Indexed keywords

DOCETAXEL;

ADVANCED CANCER; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EXPRESSED SEQUENCE TAG; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TREATMENT OUTCOME;

EID: 64549130078     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000159     Document Type: Article

References (35)

1. Kim R, Osaki A, Tanabe K and Toge T: Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB. Oncol Rep 11: 1265-1272, 2004.
2. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
3. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
4. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999.
5. Tham YL, Gomez LF, Mohsin S, et al: Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94: 279-284, 2005.
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809-820, 2006.
7. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715, 2007.
8. Zembutsu H, Yanada M, Hishida A, et al: Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol 31: 313-322, 2007.
9. Takata R, Katagiri T, Kanehira M, et al: Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 98: 113-117, 2007.
10. Kitahara O, Furukawa Y, Tanaka T, et al: Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61: 3544-3549, 2001.
11. Okabe H, Satoh S, Kato T, et al: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137, 2001.
12. Ono K, Tanaka T, Tsunoda T, et al: Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007-5011, 2000.
13. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
14. Yamanaka Y, Tamari M, Nakahata T and Nakamura Y: Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun 287: 198-203, 2001.
15. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431, 2005.
16. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532, 1994.
17. Alexandre J, Bleuzen P, Bonneterre J, et al: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18: 562-573, 2000.
18. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y and Noguchi S: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95: 255-259, 2001.
19. Hasegawa S, Miyoshi Y, Egawa C, et al: Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer 101: 46-51, 2002.
20. Arinc E, Arslan S and Adali O: Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch Toxicol 79: 427-433, 2005.
21. Gut I, Danielova V, Holubova J, Soucek P and Kluckova H: Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol 74: 437-446, 2000.
22. Soucek P, Filipcova B and Gut I: Cytochrome P450 destruction and radical scavenging by benzene and its metabolites. Evidence for the key role of quinones. Biochem Pharmacol 47: 2233-2242, 1994.
23. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB and Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 165: 397-403, 2000.
24. Sawai H, Park YW, Roberson J, Imai T, Goronzy JJ and Weyand CM: T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 52: 1392-1401, 2005.
25. Sonnet C, Lafuste P, Arnold L, et al: Human macrophages rescue myoblasts and myotubes from apoptosis through a set of adhesion molecular systems. J Cell Sci 119: 2497-2507, 2006.
26. Tsurutani J, West KA, Sayyah J, Gills JJ and Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432, 2005.
27. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/ MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
28. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
29. Cavarretta IT, Neuwirt H, Untergasser G, et al: The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26: 2822-2832, 2007.
30. Rincon M, Broadwater G, Harris L, et al: Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 100: 301-308, 2006.
31. Endo K, Takeshita T, Kasai H, et al: STAM2, a new member of the STAM family, binding to the Janus kinases. FEBS Lett 477: 55-61, 2000.
32. Yamada M, Ishii N, Asao H, et al: Signal-transducing adaptor molecules STAM1 and STAM2 are required for T-cell development and survival. Mol Cell Biol 22: 8648-8658, 2002.
33. Pandey A, Fernandez MM, Steen H, et al: Identification of a novel immunoreceptor tyrosine-based activation motif-containing molecule, STAM2, by mass spectrometry and its involvement in growth factor and cytokine receptor signaling pathways. J Biol Chem 275: 38633-38639, 2000.
34. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004.
35. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837, 2004.